A citation-based method for searching scientific literature

Jun Li, Jieyu Wang, Ruifang Chen, Yang Bai, Xin Lu. Oncotarget 2017
Times Cited: 97







List of co-cited articles
661 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.
Lin Zhang, Jose R Conejo-Garcia, Dionyssios Katsaros, Phyllis A Gimotty, Marco Massobrio, Giorgia Regnani, Antonis Makrigiannakis, Heidi Gray, Katia Schlienger, Michael N Liebman,[...]. N Engl J Med 2003
28

Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer.
Eiichi Sato, Sara H Olson, Jiyoung Ahn, Brian Bundy, Hiroyoshi Nishikawa, Feng Qian, Achim A Jungbluth, Denise Frosina, Sacha Gnjatic, Christine Ambrosone,[...]. Proc Natl Acad Sci U S A 2005
21

Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis.
Wei-Ting Hwang, Sarah F Adams, Emin Tahirovic, Ian S Hagemann, George Coukos. Gynecol Oncol 2012
379
18

Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer.
Junzo Hamanishi, Masaki Mandai, Masashi Iwasaki, Taku Okazaki, Yoshimasa Tanaka, Ken Yamaguchi, Toshihiro Higuchi, Haruhiko Yagi, Kenji Takakura, Nagahiro Minato,[...]. Proc Natl Acad Sci U S A 2007
17

Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer.
Ellen L Goode, Matthew S Block, Kimberly R Kalli, Robert A Vierkant, Wenqian Chen, Zachary C Fogarty, Aleksandra Gentry-Maharaj, Aleksandra Tołoczko, Alexander Hein, Aliecia L Bouligny,[...]. JAMA Oncol 2017
150
17

Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer.
Junzo Hamanishi, Masaki Mandai, Takafumi Ikeda, Manabu Minami, Atsushi Kawaguchi, Toshinori Murayama, Masashi Kanai, Yukiko Mori, Shigemi Matsumoto, Shunsuke Chikuma,[...]. J Clin Oncol 2015
662
16

Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma.
Silvia Darb-Esfahani, Catarina Alisa Kunze, Hagen Kulbe, Jalid Sehouli, Stephan Wienert, Judith Lindner, Jan Budczies, Michael Bockmayr, Manfred Dietel, Carsten Denkert,[...]. Oncotarget 2016
164
14


Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss.
Blaise Clarke, Anna V Tinker, Cheng-Han Lee, Subbaya Subramanian, Matt van de Rijn, Dmitry Turbin, Steve Kalloger, Guangming Han, Kathy Ceballos, Mark G Cadungog,[...]. Mod Pathol 2009
192
11

Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.
Kyle C Strickland, Brooke E Howitt, Sachet A Shukla, Scott Rodig, Lauren L Ritterhouse, Joyce F Liu, Judy E Garber, Dipanjan Chowdhury, Catherine J Wu, Alan D D'Andrea,[...]. Oncotarget 2016
356
11

Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC).
S J L Mesnage, A Auguste, C Genestie, A Dunant, E Pain, F Drusch, S Gouy, P Morice, E Bentivegna, C Lhomme,[...]. Ann Oncol 2017
96
10

The immune contexture in human tumours: impact on clinical outcome.
Wolf Herman Fridman, Franck Pagès, Catherine Sautès-Fridman, Jérôme Galon. Nat Rev Cancer 2012
10


Patient inflammatory status and CD4+/CD8+ intraepithelial tumor lymphocyte infiltration are predictors of outcomes in high-grade serous ovarian cancer.
Mauricio P Pinto, Carlos Balmaceda, Maria L Bravo, Sumie Kato, Alejandra Villarroel, Gareth I Owen, Juan Carlos Roa, Mauricio A Cuello, Carolina Ibañez. Gynecol Oncol 2018
45
22

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
10

CD20+ tumor-infiltrating lymphocytes have an atypical CD27- memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer.
Julie S Nielsen, Rob A Sahota, Katy Milne, Sara E Kost, Nancy J Nesslinger, Peter H Watson, Brad H Nelson. Clin Cancer Res 2012
303
9

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.
Tyler J Curiel, George Coukos, Linhua Zou, Xavier Alvarez, Pui Cheng, Peter Mottram, Melina Evdemon-Hogan, Jose R Conejo-Garcia, Lin Zhang, Matthew Burow,[...]. Nat Med 2004
9

Tumor infiltrating lymphocytes in ovarian cancer.
Phillip P Santoiemma, Daniel J Powell. Cancer Biol Ther 2015
160
9

The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.
R Salgado, C Denkert, S Demaria, N Sirtaine, F Klauschen, G Pruneri, S Wienert, G Van den Eynden, F L Baehner, F Penault-Llorca,[...]. Ann Oncol 2015
9

A high M1/M2 ratio of tumor-associated macrophages is associated with extended survival in ovarian cancer patients.
Meiying Zhang, Yifeng He, Xiangjun Sun, Qing Li, Wenjing Wang, Aimin Zhao, Wen Di. J Ovarian Res 2014
272
9

Neoadjuvant Chemotherapy of Ovarian Cancer Results in Three Patterns of Tumor-Infiltrating Lymphocyte Response with Distinct Implications for Immunotherapy.
Charlotte S Lo, Sanaz Sanii, David R Kroeger, Katy Milne, Aline Talhouk, Derek S Chiu, Kurosh Rahimi, Patricia A Shaw, Blaise A Clarke, Brad H Nelson. Clin Cancer Res 2017
89
8

Hallmarks of cancer: the next generation.
Douglas Hanahan, Robert A Weinberg. Cell 2011
8

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome.
Jérôme Galon, Anne Costes, Fatima Sanchez-Cabo, Amos Kirilovsky, Bernhard Mlecnik, Christine Lagorce-Pagès, Marie Tosolini, Matthieu Camus, Anne Berger, Philippe Wind,[...]. Science 2006
8



The role of immune checkpoint inhibition in the treatment of ovarian cancer.
Stéphanie L Gaillard, Angeles A Secord, Bradley Monk. Gynecol Oncol Res Pract 2016
90
8

Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors.
Katy Milne, Martin Köbel, Steven E Kalloger, Rebecca O Barnes, Dongxia Gao, C Blake Gilks, Peter H Watson, Brad H Nelson. PLoS One 2009
275
7

Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial.
Sean Kehoe, Jane Hook, Matthew Nankivell, Gordon C Jayson, Henry Kitchener, Tito Lopes, David Luesley, Timothy Perren, Selina Bannoo, Monica Mascarenhas,[...]. Lancet 2015
624
7

Immunity, inflammation, and cancer.
Sergei I Grivennikov, Florian R Greten, Michael Karin. Cell 2010
7

Classifying Cancers Based on T-cell Infiltration and PD-L1.
Michele W L Teng, Shin Foong Ngiow, Antoni Ribas, Mark J Smyth. Cancer Res 2015
825
7

Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: Analysis of KEYNOTE-028.
Andrea Varga, Sarina Piha-Paul, Patrick A Ott, Janice M Mehnert, Dominique Berton-Rigaud, Anne Morosky, Ping Yang, Jane Ruman, Daniela Matei. Gynecol Oncol 2019
105
7

Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial.
Mary L Disis, Matthew H Taylor, Karen Kelly, J Thaddeus Beck, Michael Gordon, Kathleen M Moore, Manish R Patel, Jorge Chaves, Haeseong Park, Alain C Mita,[...]. JAMA Oncol 2019
167
7

Prognostic significance of tumor-associated macrophages in ovarian cancer: A meta-analysis.
Xia Yuan, Jing Zhang, Dan Li, Ye Mao, Fei Mo, Wei Du, Xuelei Ma. Gynecol Oncol 2017
107
7

Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study.
U A Matulonis, R Shapira-Frommer, A D Santin, A S Lisyanskaya, S Pignata, I Vergote, F Raspagliesi, G S Sonke, M Birrer, D M Provencher,[...]. Ann Oncol 2019
226
7

Ovarian cancer development and metastasis.
Ernst Lengyel. Am J Pathol 2010
915
7

The comprehensive assessment of local immune status of ovarian cancer by the clustering of multiple immune factors.
Junzo Hamanishi, Masaki Mandai, Kaoru Abiko, Noriomi Matsumura, Tsukasa Baba, Yumiko Yoshioka, Kenzo Kosaka, Ikuo Konishi. Clin Immunol 2011
52
11

Foxp3(+) cell infiltration and granzyme B(+)/Foxp3(+) cell ratio are associated with outcome in neoadjuvant chemotherapy-treated ovarian carcinoma.
Martin Pölcher, Michael Braun, Nicolaus Friedrichs, Christian Rudlowski, Eva Bercht, Rolf Fimmers, Axel Sauerwald, Mignon-Denise Keyver-Paik, Kirsten Kübler, Reinhard Büttner,[...]. Cancer Immunol Immunother 2010
52
11

Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.
Ignace Vergote, Claes G Tropé, Frédéric Amant, Gunnar B Kristensen, Tom Ehlen, Nick Johnson, René H M Verheijen, Maria E L van der Burg, Angel J Lacave, Pierluigi Benedetti Panici,[...]. N Engl J Med 2010
6

The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis.
M J M Gooden, G H de Bock, N Leffers, T Daemen, H W Nijman. Br J Cancer 2011
760
6

Association between tumour infiltrating lymphocytes, histotype and clinical outcome in epithelial ovarian cancer.
Fiona R James, Mercedes Jiminez-Linan, Jennifer Alsop, Marie Mack, Honglin Song, James D Brenton, Paul D P Pharoah, H Raza Ali. BMC Cancer 2017
29
20

Tumor infiltrating lymphocytes and survival in patients with head and neck squamous cell carcinoma.
Nghia Nguyen, Emily Bellile, Daffyd Thomas, Jonathan McHugh, Laura Rozek, Shama Virani, Lisa Peterson, Thomas E Carey, Heather Walline, Jeffery Moyer,[...]. Head Neck 2016
181
6

The Prognostic Value of Tumor-Infiltrating Lymphocytes in Breast Cancer: A Systematic Review and Meta-Analysis.
Yan Mao, Qing Qu, Xiaosong Chen, Ou Huang, Jiayi Wu, Kunwei Shen. PLoS One 2016
127
6

A phase 3 trial of bevacizumab in ovarian cancer.
Timothy J Perren, Ann Marie Swart, Jacobus Pfisterer, Jonathan A Ledermann, Eric Pujade-Lauraine, Gunnar Kristensen, Mark S Carey, Philip Beale, Andrés Cervantes, Christian Kurzeder,[...]. N Engl J Med 2011
6

Whole-genome characterization of chemoresistant ovarian cancer.
Ann-Marie Patch, Elizabeth L Christie, Dariush Etemadmoghadam, Dale W Garsed, Joshy George, Sian Fereday, Katia Nones, Prue Cowin, Kathryn Alsop, Peter J Bailey,[...]. Nature 2015
810
6


Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome.
Richard W Tothill, Anna V Tinker, Joshy George, Robert Brown, Stephen B Fox, Stephen Lade, Daryl S Johnson, Melanie K Trivett, Dariush Etemadmoghadam, Bianca Locandro,[...]. Clin Cancer Res 2008
931
6

Neoadjuvant Chemotherapy Modulates the Immune Microenvironment in Metastases of Tubo-Ovarian High-Grade Serous Carcinoma.
Steffen Böhm, Anne Montfort, Oliver M T Pearce, Joanne Topping, Probir Chakravarty, Gemma L A Everitt, Andrew Clear, Jackie R McDermott, Darren Ennis, Thomas Dowe,[...]. Clin Cancer Res 2016
82
6

Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer.
Sarah F Adams, Douglas A Levine, Mark G Cadungog, Rachel Hammond, Andrea Facciabene, Narciso Olvera, Stephen C Rubin, Jeff Boyd, Phyllis A Gimotty, George Coukos. Cancer 2009
87
5

Tumor-associated macrophages: from mechanisms to therapy.
Roy Noy, Jeffrey W Pollard. Immunity 2014
5

Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies.
Kristin G Anderson, Ingunn M Stromnes, Philip D Greenberg. Cancer Cell 2017
282
5


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.